BioCentury
ARTICLE | Clinical News

T902611: TLRK said it discontinued development of T611 in order to focus its clinical efforts. The company said studies of T611, which was in Phase II testing f

June 17, 2002 7:00 AM UTC

Tularik Inc. (TLRK), South San Francisco, Calif. Product: T902611 (T611) Business: Infectious diseases Therapeutic category: Viral replication Target: CMV primase Description: Selective inhibitor of ...